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ABSTRACT
ObjeCtive
To compare the effectiveness of alternative first line 
treatment options for women with WHO group II 
anovulation wishing to conceive.
Design
Systematic review and network meta-analysis.
Data sOurCes
Cochrane Central Register of Controlled Trials, Medline, 
and Embase, up to 11 April 2016.
stuDy seleCtiOn
Randomised controlled trials comparing eight 
ovulation induction treatments in women with WHO 
group II anovulation: clomiphene, letrozole, 
metformin, clomiphene and metformin combined, 
tamoxifen, gonadotropins, laparoscopic ovarian 
drilling, and placebo or no treatment. Study quality 
was measured on the basis of the methodology and 
categories described in the Cochrane Collaboration 
Handbook. Pregnancy, defined preferably as clinical 
pregnancy, was the primary outcome; live birth, 
ovulation, miscarriage, and multiple pregnancy were 
secondary outcomes.
results
Of 2631 titles and abstracts initially identified, 57 trials 
reporting on 8082 women were included. All 
pharmacological treatments were superior to placebo 
or no intervention in terms of pregnancy and ovulation. 
Compared with clomiphene alone, both letrozole and 
the combination of clomiphene and metformin showed 
higher pregnancy rates (odds ratio 1.58, 95% 
confidence interval 1.25 to 2.00; 1.81, 1.35 to 2.42; 
respectively) and ovulation rates (1.99, 1.38 to 2.87; 
1.55, 1.02 to 2.36; respectively). Letrozole led to higher 
live birth rates when compared with clomiphene alone 
(1.67, 1.11 to 2.49). Both letrozole and metformin led to 
lower multiple pregnancy rates compared with 
clomiphene alone (0.46, 0.23 to 0.92; 0.22, 0.05 to 
0.92; respectively).
COnClusiOns
In women with WHO group II anovulation, letrozole and 
the combination of clomiphene and metformin are 
superior to clomiphene alone in terms of ovulation and 
pregnancy. Compared with clomiphene alone, 
letrozole is the only treatment showing a significantly 
higher rate of live birth.
systematiC review registratiOn
PROSPERO CRD42015027579.
Introduction
Infertility affects one in seven couples, and ovulation 
disorders account for a quarter of all cases.1  Normogo-
nadotrophic anovulation, also classified as World 
Health Organization group II anovulation, is the most 
common category of anovulatory infertility. Within this 
group, polycystic ovary syndrome (PCOS) is by far the 
most prevalent cause.2
PCOS was first described in 1935 by Stein and 
 Leventhal.3  Previously described in several different 
ways, the diagnostic criteria for PCOS, agreed jointly 
by the European Society of Human Reproduction 
and Embryology and the American Society for Repro-
ductive Medicine, are known as the Rotterdam crite-
ria.4 5  These criteria are also endorsed by the 
Endocrine Society6  and are used by a wide range of 
medical professionals, and not just obstetricians 
and gynaecologists. The clinical manifestations of 
PCOS include oligomenorrhoea or amenorrhoea, hir-
sutism, and frequently infertility.7  From conception, 
women with PCOS and their infants are at increased 
risk of perinatal complications, including gesta-
tional diabetes, pre-eclampsia, preterm labour, and 
neonatal morbidity.8-10
Safe and effective ovulation induction is important 
for women with WHO group II anovulation who wish to 
conceive, to avoid premature exposure to in vitro fertil-
isation, which is invasive, expensive, and associated 
with potentially higher chances of perinatal complica-
tions and congenital abnormalities.11-14 Several medical 
options are used to treat ovulation disorders and infer-
tility, including oestrogen receptor modulators (such as 
clomiphene and tamoxifen), aromatase inhibitors 
(such as letrozole), insulin sensitising drugs (such as 
metformin), and direct hormonal stimulation of the 
WhAT IS AlReAdy knoWn on ThIS TopIC
Clomiphene is the longstanding first line treatment for WHO group II anovulation
Existing pairwise meta-analyses are limited to comparisons of two treatments
WhAT ThIS STudy AddS
This study compares all of the most common regimens of ovulation induction with 
each other, using direct and indirect means
All pharmacological ovulation inductions were superior to placebo or no treatment 
in terms of ovulation and pregnancy in women with WHO group II anovulation
Letrozole was the most effective treatment in terms of live birth, and one of the top 
three treatments in terms of pregnancy and ovulation
Clomiphene and metformin combined was the most effective treatment in terms of 
pregnancy but not live birth; the potential higher chances of side effects should 
also be taken into account in decision making
Metformin and letrozole were associated with the lowest rates of multiple pregnancy
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ovaries (gonadotropins), with laparoscopic ovarian 
drilling being a surgical alternative.
Traditional pairwise meta-analysis only allows 
the  comparison of two interventions for ovulation 
induction.15-20  However, many of these treatment strat-
egies have not been compared directly in previous ran-
domised controlled trials. Therefore, it is difficult to 
identify the most effective treatment based on direct 
evidence. Network meta-analysis, also known as multi-
ple treatment comparison meta-analysis, compares 
multiple treatments in one statistical model,21-23  and 
provides a hierarchy of effectiveness of these treatments 
that can guide decision making.24 25 The application of 
network meta-analysis is crucial in areas where multi-
ple interventions are available, such as in WHO group II 
anovulation.
We therefore performed a systematic review and net-
work meta-analysis to compare the effectiveness of dif-
ferent treatment options, including clomiphene, 
letrozole, metformin, clomiphene and metformin com-
bined, tamoxifen, gonadotropins, laparoscopic ovarian 
drilling, and placebo or no treatment, in women with 
WHO group II anovulation, and to identify the best 
strategy for first line treatment.
Methods
search strategy and selection criteria
We conducted and reported the study according to the 
preferred reporting items for systematic reviews and 
meta-analyses (PRISMA) extension statement for net-
work meta-analyses.26 We performed an extensive elec-
tronic search of the Cochrane Central Register of 
Controlled Trials (CENTRAL), Medline, and Embase for 
randomised controlled trials. The search strategies 
were based on combinations of ovulation induction and 
anovulation (or PCOS), using both free words and index 
terms (appendix 1). We sought further trial details or 
protocols to establish eligibility of potential trials. We 
also searched previous published Cochrane systematic 
reviews on ovulation induction for additional studies. 
No language restrictions were applied. Our latest search 
was completed on 11 April 2016.
We included published and unpublished randomised 
controlled trials comparing one or more common ovu-
lation induction options with placebo, no treatment, or 
other treatments: clomiphene, tamoxifen, letrozole, 
metformin, gonadotropins, laparoscopic ovarian drill-
ing, or the combination of clomiphene and metformin. 
Treatments were categorised according to the initial 
randomised allocation, although subsequent clinical 
management might have included further doses or an 
alternative treatment.
Studies were excluded if they were not randomised 
controlled trials; only included treatment resistant 
women; or failed to report on clinical pregnancy, live 
birth, or pregnancy. Participants in the included studies 
were classified as: treatment naive women, a combina-
tion of treatment naive and treatment exposed women, 
and women whose treatment status was unknown. 
Crossover trials were also included if pre-crossover data 
were available. We also excluded those studies that 
only compared different doses of the same treatment 
option or compared the effects of adding medical 
adjuncts such as dexamethasone. Authors were con-
tacted for further information if necessary.
Patient involvement
There was no patient involvement in framing the 
research question, choosing the outcome measures, or 
conducting the research. We plan to involve Fertility 
Network UK, PCOS Challenge, RESOLVE, and Access 
Australia's National Infertility Network in the dissemi-
nation of the research results by means of short, easy to 
read summaries of key results, infographics, and audio 
or video interviews that can be used by patients and 
caregivers.
Data extraction and assessment of risk of bias
Two reviewers (RW and BVK) independently assessed 
the eligibility of all identified citations, and extracted 
data from original trial reports using a specifically 
designed form that captured information on study 
design, trial setting, patient characteristics (inclusion 
criteria, age, body mass index, duration of infertility, 
history of ovulation induction), sample sizes, details of 
ovulation induction options, and outcomes. Disagree-
ments were referred to a third reviewer (BWJM) to reach 
consensus.
We chose pregnancy, defined preferably as clinical 
pregnancy, as the primary outcome. Clinical pregnancy 
was defined as pregnancy diagnosed by ultrasono-
graphic visualisation of one or more gestational 
sacs.27 28  Comparing the effectiveness of a treatment 
based on either clinical pregnancy or live birth rate as 
endpoints often results in comparable conclusions.29 
Therefore, we used data on live birth or pregnancy (pos-
itive blood or urine test for human chorionic gonadotro-
pin) as an outcome when data on clinical pregnancy 
were not available. Secondary outcomes were live birth, 
ovulation, miscarriage, and multiple pregnancy.
Study quality was assigned by two reviewers (RW and 
BVK) using the methodology and categories described 
in the Cochrane Collaboration Handbook.30  Again, in 
case of disagreement, a third reviewer (BWJM) was 
asked to reach consensus. Briefly, the tool for assessing 
risk of bias addresses seven specific domains: random 
sequence generation, allocation concealment, blinding 
of participants and personnel, blinding of outcome 
assessment, incomplete outcome data, selective report-
ing, and other sources of bias. Each domain is assigned 
a judgment relating to the risk of bias for that study 
classified as low risk, high risk, or unclear. We pre-
sented risk of bias graphs by Review Manager 5.3 soft-
ware.30
Data synthesis and statistical analysis
A network meta-analysis was conducted to simultane-
ously compare seven treatment options for ovulation 
induction and placebo or no treatment for each out-
come. In its simplest form, a network meta-analysis is 
the combination of direct and indirect estimates of rela-
tive treatment effect in one analysis. An indirect 
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 estimate of the relative treatment effect A versus B can 
be formed by comparing direct trials of A versus C with 
trials of B versus C. Network plots were constructed to 
illustrate the geometry of the network.31
All network meta-analyses were conducted within a 
random effects multiple regression model using the 
mvmeta package in Stata software 31 32 (version 12.0, Stata 
Corp). Where direct data were available, pairwise 
meta-analyses in random effects model were also per-
formed in Stata and the agreement of direct and indirect 
evidence was assessed by an inconsistency plot. Studies 
with 0% or 100% events in all interventions were 
excluded from the analysis because these studies do not 
allow conclusions on relative effects. For studies with 
zero events in one arm only, we added a continuity cor-
rection of 0.5 to each cell. To avoid double counting of 
events, multi-intervention trials were analysed in their 
original form without the need to combine interventions.
For the network meta-analysis, we presented sum-
mary treatment effects (odds ratios) with their 95% con-
fidence intervals as well as predictive intervals to 
facilitate interpretation of the results in the light of the 
magnitude of heterogeneity.31  Predictive intervals can 
provide an interval within which the estimate of a 
future study is expected to be.31  We applied the compar-
ison adjusted funnel plot to assess small study effects in 
the network. We used the surface under the cumulative 
ranking curve to rank the treatments.31 33 It is a percent-
age of the effectiveness of every treatment relative to an 
imaginary treatment that is always the best without 
uncertainty. We then performed sensitivity analysis to 
explore important network inconsistency. We restricted 
the analysis to those trials on treatment naive women, 
trials with low risk of randomisation and allocation 
bias, and trials reporting clinical pregnancy for sensi-
tivity analysis.
Results
Characteristics of included studies
The literature search yielded 2631 publications, as 
shown in the PRISMA flowchart (fig 1 ). Fifty six34-89 
publications reporting on 57 trials fulfilled the eligibil-
ity criteria, as one study56 included two individual trials 
(appendices 2 and 3).Five studies35 36 47 52 67  were cross-
over studies and eight studies35 44 54 61 66 77 86 87  were 
reported in conference abstracts. Publication dates 
ranged from 1966 to 2015, with 45 trials published in the 
last 10 years. The studies were conducted in various 
countries, and one study each was reported in French,46 
Italian,80  Turkish,39  and Persian.69 The list of excluded 
studies is presented in appendix 4.
Of 57 trials, seven54 56 58 60 64 82 88 had three comparison 
interventions and each of the remaining 50 trials had 
two. Overall, 8082 women with WHO group II anovula-
tion were randomised to seven different treatment 
options (including clomiphene, letrozole, metformin, 
clomiphene and metformin combined, tamoxifen, 
gonadotropins, and laparoscopic ovarian drilling) and 
to placebo or no treatment. Appendix 5 presents the 
network plots for pregnancy, live birth, ovulation, mis-
carriage, and multiple pregnancy.
risk of bias assessment results
There were 31 (54%) randomised controlled trials with 
low risk of bias on random sequence generation and 25 
(44%) randomised controlled trials with low risk of bias 
on allocation concealment. Only 12 (21%) trials had low 
risk of bias on both blinding of participants and out-
come assessment. Appendix 6 shows results from the 
risk of bias assessment. 
network meta-analysis results
Primary outcome—pregnancy
Our network meta-analysis included 57 randomised 
controlled trials reporting on 8082 women. Of these tri-
als, 19 evaluated a combination of clomiphene and met-
formin (1031 women). The remaining trials offered one 
treatment in each intervention, including clomiphene 
(52 trials; 3511 women), letrozole (21; 1758), metformin 
alone (14; 910), tamoxifen (four; 327), follicle stimulat-
ing hormone (two; 197), laparoscopic ovarian drilling 
(one; 36), and placebo or no treatment (eight; 312).
Figure 2  and table 1 show the network meta-analysis 
results. Compared with placebo or no intervention, all 
the treatment options (except for laparoscopic ovarian 
drilling) resulted in a significantly higher chance of 
pregnancy. Compared with clomiphene alone, letrozole 
as well as the combination of clomiphene and 
 metformin led to significantly higher pregnancy rates 
(odds ratio 1.58, 95% confidence interval 1.25 to 2.00; 
1.81, 1.35 to 2.42; respectively). Similar differences could 
be found when we compared these two interventions 
with tamoxifen. The combination of clomiphene and 
metformin also led to a significantly higher pregnancy 
when compared with metformin alone (1.71, 1.15 to 2.53). 
When we considered predictive intervals in a network 
meta-analysis, clomiphene, letrozole, metformin, 
Records aer duplicates removed (n=2631)
Full text articles* assessed for eligibility (n=101)
Publications included in systematic review
and network meta-analysis (n=56)
Trials (n=57)
Additional records identied
through other sources:
Studies included
in published Cochrane
Reviews (n=11)
Records identied through
database searching (n=4092):
  MEDLINE (n=861)
  EMBASE (n=2471)
  CENTRAL (n=760)
Records excluded (n=2530)
Full text articles excluded (n=45):
  Overlapping population (n=23)
  Not randomised controlled trials (n=8)
  No primary outcome (n=5)
  Data unavailable (n=3)
  Wrong interventions (n=5)
  Inappropriate study population (n=1)
Fig 1 | Prisma flow diagram of literature search for 
randomised controlled trials comparing eight ovulation 
induction treatments in women with wHO group ii 
anovulation. *Full text articles=including abstract only 
publications
doi: 10.1136/bmj.j138 | BMJ 2017;356:j138 | the bmj
RESEARCH
4
 follicle stimulating hormone, and clomiphene and met-
formin combined still led to higher pregnancy rates 
compared with placebo or no intervention. For those 
interventions compared directly, the results from pair-
wise meta-analysis and network meta-analysis were 
consistent, apart from follicle stimulating hormone ver-
sus clomiphene (table 1 and appendix 7). 
The surface under the cumulative ranking curve was 
used to provide a hierarchical ranking of the different 
treatments. The efficacy of every intervention, 
expressed as a percentage, was considered in relation to 
an imaginary intervention assumed to be the best. 
Higher surface under the cumulative ranking curve val-
ues therefore correspond to more effective treatments.31 
The surface under the cumulative ranking curve values 
for the eight ovulation induction regimens were 90%, 
82%, 80%, 50%, 46%, 27%, 22%, and 3%, for clomi-
phene and metformin combined, follicle stimulating 
hormone, letrozole, metformin, clomiphene, tamoxi-
fen, laparoscopic ovarian drilling, and placebo or no 
treatment, respectively (appendix 8). Further details of 
the analyses on the primary outcome are presented in 
appendices 9-11.
Secondary outcomes
Live birth—For the outcome live birth, 23 randomised 
controlled trials with 4206 women were included in the 
network meta-analysis. Letrozole resulted in a signifi-
cantly higher live birth rate compared with clomiphene 
(odds ratio 1.67, 95% confidence interval 1.11 to 2.49) and 
metformin led to lower live birth rate than letrozole 
(0.54; 0.29 to 0.98). The other comparisons showed no 
significant differences (appendix 12).
In terms of live birth, letrozole had the highest surface 
under the cumulative ranking curve value (81%), fol-
lowed by follicle stimulating hormone (74%), clomi-
phene and metformin combined (71%), tamoxifen (48%), 
clomiphene (36%), and metformin (30%), while placebo 
or no treatment (10%) had the lowest surface under the 
cumulative ranking curve value (appendix 13).
Clomiphene citrate versus
  Placebo/no treatment
  Letrozole
  Metformin
  Clomiphene citrate + metformin
  Tamoxifen
  Follicle stimulating hormone
  Laparoscopic ovarian drilling
Placebo/no treatment versus
  Letrozole
  Metformin
  Clomiphene citrate + metformin
  Tamoxifen
  Follicle stimulating hormone
  Laparoscopic ovarian drilling
Letrozole versus
  Metformin
  Clomiphene citrate + metformin
  Tamoxifen
  Follicle stimulating hormone
  Laparoscopic ovarian drilling
Metformin versus
  Clomiphene citrate + metformin
  Tamoxifen
  Follicle stimulating hormone
  Laparoscopic ovarian drilling
Clomiphene citrate + metformin versus
  Tamoxifen
  Follicle stimulating hormone
  Laparoscopic ovarian drilling
Tamoxifen versus
  Follicle stimulating hormone
  Laparoscopic ovarian drilling
Follicle stimulating hormone versus
  Laparoscopic ovarian drilling
0.30 (0.15 to 0.58)
1.58 (1.25 to 2.00)
1.06 (0.75 to 1.50)
1.81 (1.35 to 2.42)
0.72 (0.42 to 1.22)
1.69 (0.85 to 3.37)
0.52 (0.15 to 1.79)
5.35 (2.63 to 10.87)
3.58 (1.93 to 6.63)
6.11 (3.02 to 12.38)
2.43 (1.03 to 5.73)
5.71 (2.18 to 15.00)
1.77 (0.44 to 7.22)
0.67 (0.45 to 1.01)
1.14 (0.79 to 1.65)
0.45 (0.26 to 0.80)
1.07 (0.52 to 2.21)
0.33 (0.09 to 1.16)
1.71 (1.15 to 2.53)
0.68 (0.36 to 1.28)
1.59 (0.74 to 3.45)
0.50 (0.14 to 1.78)
0.40 (0.22 to 0.73)
0.93 (0.44 to 1.97)
0.29 (0.08 to 1.03)
2.35 (0.99 to 5.60)
0.73 (0.19 to 2.78)
0.31 (0.08 to 1.27)
0.1 0.3 1 5 20
Comparison Odds ratio
(95% CI)
(0.11 to 0.81)
(0.74 to 3.39)
(0.47 to 2.37)
(0.83 to 3.95)
(0.29 to 1.78)
(0.61 to 4.65)
(0.12 to 2.25)
(1.91 to 14.94)
(1.37 to 9.37)
(2.19 to 17.04)
(0.78 to 7.60)
(1.67 to 19.50)
(0.35 to 8.91)
(0.29 to 1.55)
(0.50 to 2.59)
(0.18 to 1.15)
(0.38 to 3.03)
(0.08 to 1.45)
(0.74 to 3.91)
(0.26 to 1.79)
(0.54 to 4.67)
(0.11 to 2.22)
(0.15 to 1.03)
(0.33 to 2.68)
(0.07 to 1.28)
(0.74 to 7.41)
(0.15 to 3.45)
(0.06 to 1.57)
(95% PrI)
Odds ratio
(95% CI)
Fig 2 | network meta-analysis of effectiveness of treatment options for pregnancy in women with wHO group ii 
anovulation. blue squares=estimate summary odds ratios of each comparison; black horizontal lines=confidence 
intervals; blue horizontal lines (overall length of lines)=predictive intervals (Pri); blue vertical line=line of no effect (odds 
ratio=1). Odds ratios less than 1 favour the first intervention; odds ratios greater than 1 favour the second intervention 
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Ovulation—For the outcome ovulation per woman 
randomised, 40 randomised controlled trials were 
included in the network meta-analysis. Compared with 
placebo, all interventions except for laparoscopic ovar-
ian drilling led to a significantly higher ovulation rate. 
These associations remained similar in the network 
meta-analysis including predictive intervals.
Letrozole (odds ratio 1.99, 95% confidence interval 
1.38 to 2.87) and the combination of clomiphene and 
metformin (1.55, 1.02 to 2.36) led to a higher ovulation 
rate than clomiphene alone (appendix 14). The 
 combination of clomiphene and metformin was supe-
rior to metformin alone (2.66, 1.54 to 4.60), while met-
formin was inferior to clomiphene alone (0.58, 0.37 to 
0.93). Both metformin (0.29, 0.17 to 0.52) and tamoxifen 
(0.37, 0.16 to 0.81) were inferior to letrozole.
Follicle stimulating hormone had the highest surface 
under the cumulative ranking curve value (88%) in 
terms of ovulation, followed by letrozole (86%), clomi-
phene and metformin combined (75%), clomiphene 
(51%), laparoscopic ovarian drilling (39%), tamoxifen 
(36%), metformin (26%), and placebo or no treatment 
(1%; appendix 15).
Miscarriage—For the outcome miscarriage, after the 
exclusion of trials with 0% or 100% event rates in all 
interventions, we included 27 randomised controlled 
trials in the network meta-analysis. We did not find any 
significant difference between each comparison in 
terms of miscarriage per woman randomised or miscar-
riage per pregnancy in the network meta-analysis 
(appendices 16 and 17).
Multiple pregnancy—Twenty trials assessed the out-
come multiple pregnancy. When expressed per woman 
randomised, follicle stimulating hormone led to higher 
multiple pregnancy rates than metformin (odds ratio 
16.27, 95% confidence interval 1.59 to 166.49). This dif-
ference remained significant in network meta-analysis 
including predictive intervals. Follicle stimulating hor-
mone also led to a higher rate of multiple pregnancy 
when compared with letrozole (7.84, 1.10 to 55.90). Both 
letrozole (0.46, 0.23 to 0.92) and metformin (0.22, 0.05 to 
0.92) led to lower rates of multiple pregnancy compared 
table 1 | results from pairwise meta-analysis (where possible) and network meta-analysis for primary outcome 
(pregnancy) in women with wHO group ii anovulation
treatment comparison*
Pairwise meta-analysis network meta-analysis
no of studies Odds ratio (95% Ci) Odds ratio (95% Ci) 95% Pri
Clomiphene citrate versus:
Placebo or no treatment 3 0.20 (0.05 to 0.74) 0.30 (0.15 to 0.58) 0.11 to 0.81
Letrozole 21 1.53 (1.26 to 1.85) 1.58 (1.25 to 2.00) 0.74 to 3.39
Metformin 9 1.10 (0.62 to 1.95) 1.06 (0.75 to 1.50) 0.47 to 2.37
Clomiphene citrate + metformin 19 1.56 (1.24 to 1.97) 1.81 (1.35 to 2.42) 0.83 to 3.95
Tamoxifen 4 0.64 (0.36 to 1.12) 0.72 (0.42 to 1.22) 0.29 to 1.78
Follicle stimulating hormone 2 1.57 (1.04 to 2.37) 1.69 (0.85 to 3.37) 0.61 to 4.65
Laparoscopic ovarian drilling 1 0.52 (0.19 to 1.44) 0.52 (0.15 to 1.79) 0.12 to 2.25
Placebo or no treatment versus:
Letrozole NA NA 5.35 (2.63 to 10.87) 1.91 to 14.94
Metformin 5 3.58 (2.06 to 6.21) 3.58 (1.93 to 6.63) 1.37 to 9.37
Clomiphene citrate + metformin NA NA 6.11 (3.02 to 12.38) 2.19 to 17.04
Tamoxifen NA NA 2.43 (1.03 to 5.73) 0.78 to 7.60
Follicle stimulating hormone NA NA 5.71 (2.18 to 15.00) 1.67 to 19.50
Laparoscopic ovarian drilling NA NA 1.77 (0.44 to 7.22) 0.35 to 8.91
letrozole versus:
Metformin 1 0.73 (0.41 to 1.32) 0.67 (0.45 to 1.01) 0.29 to 1.55
Clomiphene citrate + metformin NA NA 1.14 (0.79 to 1.65) 0.50 to 2.59
Tamoxifen 1 0.67 (0.30 to 1.47) 0.45 (0.26 to 0.80) 0.18 to 1.15
Follicle stimulating hormone NA NA 1.07 (0.52 to 2.21) 0.38 to 3.03
Laparoscopic ovarian drilling NA NA 0.33 (0.09 to 1.16) 0.08 to 1.45
metformin versus:
Clomiphene citrate + metformin 5 1.92 (0.90 to 4.06) 1.71 (1.15 to 2.53) 0.74 to 3.91
Tamoxifen NA NA 0.68 (0.36 to 1.28) 0.26 to 1.79
Follicle stimulating hormone NA NA 1.59 (0.74 to 3.45) 0.54 to 4.67
Laparoscopic ovarian drilling NA NA 0.50 (0.14 to 1.78) 0.11 to 2.22
Clomiphene citrate + metformin versus:
Tamoxifen NA NA 0.40 (0.22 to 0.73) 0.15 to 1.03
Follicle stimulating hormone NA NA 0.93 (0.44 to 1.97) 0.33 to 2.68
Laparoscopic ovarian drilling NA NA 0.29 (0.08 to 1.03) 0.07 to 1.28
tamoxifen versus:
Follicle stimulating hormone NA NA 2.35 (0.99 to 5.60) 0.74 to 7.41
Laparoscopic ovarian drilling NA NA 0.73 (0.19 to 2.78) 0.15 to 3.45
Follicle stimulating hormone versus:
Laparoscopic ovarian drilling NA NA 0.31 (0.08 to 1.27) 0.06 to 1.57
PrI=predictive interval; NA=not available.
*Odds ratios less than 1 favour the first intervention; odds ratios greater than 1 favour the second intervention.
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with clomiphene alone, but these differences were not 
significant in network meta-analysis including predic-
tive intervals (appendix 18).
Follicle stimulating hormone had the highest surface 
under the cumulative ranking curve value (93%), fol-
lowed by clomiphene (70%), placebo (50%), tamoxifen 
(46%), clomiphene and metformin combined (44%), 
letrozole (34%), and metformin (14%; appendix 19).
Further details of the analyses of the secondary out-
comes are presented in appendices 20-32.
sensitivity analysis results
When analyses were restricted to studies reporting clin-
ical pregnancy (appendix 33), the results were consis-
tent with the main findings: letrozole and the 
combination of clomiphene and metformin were supe-
rior to clomiphene alone. However, in studies with 
treatment naive women or studies with low risk of both 
randomisation and allocation bias, letrozole remained 
superior to clomiphene (odds ratio 1.80, 95% confi-
dence interval 1.20 to 2.70; 1.97, 1.18 to 3.30; respec-
tively), while the difference between clomiphene and 
metformin combined and clomiphene alone was not 
significant (1.65, 0.98 to 2.80; 1.57, 0.96 to 2.57; respec-
tively) (appendices 34 and 35).
discussion
summary of key findings
Our systematic review and network meta-analysis on 
ovulation induction in infertile women with WHO 
group II anovulation has three key findings. Firstly, all 
pharmacological treatments were more effective than 
placebo or no intervention in terms of achieving ovula-
tion and pregnancy. Secondly, the combination of clo-
miphene and metformin as well as letrozole on its own 
were superior to clomiphene in terms of ovulation and 
pregnancy, and letrozole was superior to clomiphene in 
terms of live birth. Lastly, both metformin and letrozole 
were associated with a lower risk of multiple pregnancy 
when compared with clomiphene.
strengths and limitations
To our knowledge, this is the first application of net-
work meta-analysis in ovulation induction, analysing 
all the available data and providing a unique opportu-
nity to rank ovulation induction treatments in one 
pooled analysis. We reported all major reproductive 
outcomes in infertility trials and performed sensitivity 
analyses in different dimensions, including study pop-
ulation and study quality. We made these attempts to 
guarantee the stability of the results. Another strength 
of our systematic review was the fact that we did not 
exclude non-English articles or trials published as 
abstracts only. These trials are often excluded from 
other meta-analyses,19 20 90 but in our meta-analysis 
they contributed 21% (12/57) of studies and 16% 
(1321/8082) of women. Therefore, we believe that our 
analysis included all relevant published randomised 
controlled trials on ovulation induction in WHO group 
II anovulation, thus reducing publication bias as much 
as possible.
Our study also had limitations. Firstly, we only 
reported reproductive outcomes in our study and were 
unable to include other relevant outcomes such as side 
effects that were not reported in many of the primary 
publications, and the reporting strategies varied from 
study to study. Metformin, for example, is known to 
generate gastrointestinal side effects,15  but this could 
not be analysed in our network meta-analysis because 
it was not systematically reported in all studies. The use 
of standardised outcomes in studies on ovulation 
induction would have improved this aspect of our sys-
tematic review.27 28 91 Additional discussion on the side 
effects of clomiphene and metformin combined is avail-
able in appendices 36-38.
Secondly, we chose pregnancy, defined preferably as 
clinical pregnancy, as the primary outcome. Although 
the aim of infertile couples is to have a healthy child, 
the overall sample size of studies reporting on preg-
nancy was significantly higher than the sample size of 
studies reporting on live birth. Studies published in the 
early 2000s or earlier usually followed up participants 
until pregnancy. To make full use of these data and 
improve the validity of the transitivity assumption of 
comparisons among the network, we chose pregnancy 
as the primary outcome. The conclusions on the effec-
tiveness of a treatment point are often, but not always in 
women with PCOS,92  in the same direction when based 
either on pregnancy or live birth, while conclusions 
based on pregnancy as an endpoint are more robust 
because they have more statistical power.29  Ideally, 
future randomised controlled trials should adhere to 
table 2 | recommendations on first line ovulation induction from current guidelines and consensus
guidelines/consensus Condition First line ovulation induction
WHO guideline, 2016102 PCOS Clomiphene or letrozole
Australian National Health and Medical Research Council (NHMRC) guideline, 2015 updated104 PCOS Clomiphene or letrozole
American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS 
Society Disease State Clinical Review, 2015103
PCOS Clomiphene or letrozole
Italian Society of Endocrinology consensus, 2015106 PCOS Clomiphene
European Society of Endocrinology position statement, 2014105 PCOS Clomiphene
Endocrine Society, 20136 PCOS Clomiphene or letrozole
National Institute for Health and Care Excellence guideline, 20131 WHO II 
anovulation
Clomiphene, metformin, or 
clomiphene and metformin combined
Society of Obstetricians and Gynaecologists of Canada guideline, 2010109 PCOS Clomiphene
ESHRE/ASRM consensus, 2008107108 PCOS Clomiphene
PCOS=polycystic ovary syndrome; ESHRE/ASRM=European Society of Human Reproduction and Embryology/American Society for Reproductive Medicine.
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the Harbin consensus on outcomes reporting in infertil-
ity trials.27 28
Thirdly, lifestyle intervention was not analysed in 
this study. Although lifestyle intervention is recom-
mended in many countries because it leads to higher 
spontaneous ovulation rates93  and natural conceptions 
rates,94  the role of lifestyle intervention in conjunction 
to drug treatment is controversial in current evidence. 
According to a recent Dutch study, lifestyle intervention 
preceding infertility treatment does not lead to better 
reproductive outcomes within two years in obese infer-
tile women,94  whereas lifestyle modification with 
weight loss before ovulation induction improved ovula-
tion and live birth in PCOS in a US study.95
Lastly, WHO group II anovulation is a heterogeneous 
condition with various clinical manifestations. Women 
with different genetic backgrounds or metabolic condi-
tions might respond differently to treatment options. 
The current systematic review only allowed general 
comparisons among women with WHO group II anovu-
lation. Owing to the various reporting strategies, we 
chose not to perform subgroup analysis, based on char-
acteristics such as body mass index and hyperandroge-
naemia status in this network meta-analysis. Apart 
from the logistical and governance issues associated 
with data sharing across different countries, asking the 
original authors to reanalyse the data can be challeng-
ing, in view of the substantial time and effort needed to 
perform secondary analysis. Additionally, there are sev-
eral practical difficulties with post hoc selection of cut-
off values for continuous variables like body mass 
index. If the distribution of participants according to 
biological cut-off values (body mass index 25 or 30) are 
not balanced across groups, the results of subgroup 
analysis using this cut-off value could be misleading. 
Individual participant data meta-analysis would be 
able to address this issue and allow a more person-
alised strategy for ovulation induction care.
research implications
Traditionally, the effectiveness of a new treatment 
option comes from comparisons with placebo or current 
standard care. To date, no trials have compared letro-
zole with placebo in treatment naive women. The cur-
rent network meta-analysis, however, provides insight 
in this comparison from indirect comparisons, and sug-
gests that trials comparing letrozole with placebo are 
unnecessary and in our opinion even unethical. Evi-
dence on a head-to-head comparison between letrozole 
and the combination of clomiphene and metformin is 
lacking. Therefore, new trials comparing these two 
interventions are needed. Future trials should also com-
pare new treatment options or combinations with one 
of these two strategies to enrich the evidence on first 
line management of WHO group II anovulation.
Current evidence showed similar miscarriage rates in 
women with metformin compared with women with 
other ovulation induction interventions during the peri-
conceptional period. Future studies on metformin use 
during pregnancy in women with WHO group II anovu-
lation, including PCOS, can be beneficial.
Individual participant data meta-analysis on this 
topic is a necessary next step to find target populations 
for different ovulation induction interventions and 
therefore to provide evidence for personally targeted 
infertility care.
Clinical implications and conclusion
In women with WHO group II anovulation including 
anovulatory PCOS, expectant management is not rec-
ommended, because pharmacological ovulation induc-
tion significantly improves pregnancy rate (odds ratios 
2.43-6.11) compared with placebo no treatment in the 
present study.
Letrozole can be recommended as first line treatment 
due to its higher ovulation, pregnancy, and live birth 
rate as well as lower multiple pregnancy rate, although 
the reluctance to adapt such new therapy is common in 
clinical practice.96  The superiority of letrozole over clo-
miphene was stable in all sensitivity analyses including 
modifying the criteria of population (treatment naive), 
reporting strategies (reporting clinical pregnancy) and 
quality of included studies (low risk of randomisation 
and allocation bias). Miscarriage is often discussed in 
the literature especially in women with PCOS, and data 
in relation to this are controversial.97 In our study, there 
were no significant differences in miscarriage rates in 
different comparisons; therefore, the superiority of 
letrozole over clomiphene in terms of live birth does not 
seem to be related to a decreased miscarriage rate.
Clomiphene and metformin combined can also be 
recommended as first line treatment, despite the lack of 
evidence to improve live birth rates and the instability 
in sensitivity analyses.29 Of 19 studies comparing clomi-
phene and metformin combined with clomiphene or 
metformin alone, only seven reported live birth. The 
reduced sample size in the analysis of live birth affected 
statistical power for this comparison, and could explain 
the lack of a significant difference between clomiphene 
and metformin combined and clomiphene alone. The 
potential higher chances of side effects should also be 
taken into account in decision making.
Clomiphene alone was not competitive in the net-
work, in terms of effectiveness (pregnancy, live birth, 
and ovulation) or safety (multiple pregnancy). Gonado-
tropins, though an effective treatment option, had the 
greatest probability of leading to multiple pregnancy. It 
is therefore not recommended to use gonadotropins as 
the first line treatment in treatment naive women with 
WHO group II anovulation. Further discussions on 
quality of evidence and interpretation of data is pre-
sented in appendix 36.
Despite the promising results shown in this study, 
neither letrozole nor metformin are approved for the 
treatment of anovulation in many countries and con-
tinue to be used off-label.98 99  The use of letrozole for 
ovulation induction is explicitly prohibited in many 
other countries100 101  (eg, Denmark), except in approved 
clinical trials. Some guidelines6 102-104  have recom-
mended clomiphene citrate or letrozole as first line 
treatment, whereas letrozole has not been included in 
the scope of other guidelines,1 105-109  including the 
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National Institute for Health and Care Excellence 
guidelines in the UK (table 2 ).1  Safety concerns about 
letrozole use in infertility were raised in a study pre-
sented at the American Society for Reproductive Medi-
cine’s 2005 annual meeting, which showed a higher 
risk of locomotor malformations and cardiac anoma-
lies in newborns.110  However, this study was criticised 
on account of its methodological limitations, including 
small sample size of the letrozole group and inappro-
priate choice of control group.111  This study has not 
been subsequently published as a peer reviewed paper. 
According to current evidence (appendix 39), letrozole 
use in infertility, including PCOS and unexplained 
infertility, does not increase the risk of congenital 
anomalies in newborns.49 65 76 78 111-116 These results need 
to be confirmed by future studies. Moreover, there is an 
urgent need for long term follow-up data among the 
offspring of these interventions to confirm the safety of 
these interventions and help subsequent guideline 
development.
Laparoscopic ovarian drilling was usually under-
taken in clomiphene resistant women, and only one 
small randomised controlled trial on treatment naive 
women with PCOS could be included in this network 
meta-analysis. According to current evidence, includ-
ing data on long term follow-up, laparoscopic ovarian 
drilling is recommended as an effective and economic 
second line treatment for ovulation induction in women 
with clomiphene resistant PCOS.117-122
In conclusion, in women with WHO group II anovula-
tion, both letrozole and the combination of clomiphene 
and metformin are superior to clomiphene alone in 
terms of ovulation and pregnancy. Letrozole is the only 
treatment showing a significantly higher rate of live 
birth when compared with clomiphene alone.
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